J
28.59
-0.22 (-0.76%)
| Previous Close | 28.81 |
| Open | 29.29 |
| Volume | 683,512 |
| Avg. Volume (3M) | 909,576 |
| Market Cap | 1,719,625,856 |
| Price / Sales | 100.12 |
| Price / Book | 1.02 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,216.61% |
| Diluted EPS (TTM) | -1.36 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 2.23% |
| Current Ratio (MRQ) | 58.47 |
| Operating Cash Flow (TTM) | -46.00 M |
| Levered Free Cash Flow (TTM) | -27.01 M |
| Return on Assets (TTM) | -8.16% |
| Return on Equity (TTM) | -9.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Janux Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.1
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.10 |
|
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.69% |
| % Held by Institutions | 113.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 150.00 (Cantor Fitzgerald, 424.66%) | Buy |
| Median | 48.00 (67.89%) | |
| Low | 32.00 (Clear Street, 11.93%) | Buy |
| Average | 66.00 (130.85%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 18.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 02 Dec 2025 | 49.00 (71.39%) | Buy | 15.86 |
| Cantor Fitzgerald | 02 Dec 2025 | 150.00 (424.66%) | Buy | 15.86 |
| Clear Street | 02 Dec 2025 | 32.00 (11.93%) | Buy | 15.86 |
| HC Wainwright & Co. | 02 Dec 2025 | 45.00 (57.40%) | Buy | 15.86 |
| 25 Nov 2025 | 70.00 (144.84%) | Buy | 34.74 | |
| Stifel | 02 Dec 2025 | 38.00 (32.91%) | Buy | 15.86 |
| 10 Sep 2025 | 45.00 (57.40%) | Buy | 24.31 | |
| Barclays | 07 Nov 2025 | 48.00 (67.89%) | Buy | 26.48 |
| 17 Sep 2025 | 47.00 (64.39%) | Buy | 23.46 | |
| Truist Securities | 10 Sep 2025 | 100.00 (249.77%) | Buy | 24.31 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEYER ANDREW HOLLMAN | - | 33.99 | -3,333 | -113,289 |
| Aggregate Net Quantity | -3,333 | |||
| Aggregate Net Value ($) | -113,289 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 33.99 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MEYER ANDREW HOLLMAN | Officer | 01 Dec 2025 | Automatic sell (-) | 3,333 | 33.99 | 113,289 |
| MEYER ANDREW HOLLMAN | Officer | 01 Dec 2025 | Option execute | 3,333 | - | - |
| Date | Type | Details |
|---|---|---|
| 01 Dec 2025 | Announcement | Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC |
| 24 Nov 2025 | Announcement | Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC |
| 06 Nov 2025 | Announcement | Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |